推进神经药理学与神经退行性疾病治疗：弥合差距与开辟新途径。
Advancing Neuropharmacology and Neurodegenerative Disease Therapy: Bridging Gaps and Paving New Pathways.
作者信息
Leri Manuela, Vasarri Marzia
机构信息
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
出版信息
Pharmaceuticals (Basel). 2025 Apr 22;18(5):606. doi: 10.3390/ph18050606.
Abstract
The Special Issue of , titled "Multi-target drug treatments for neurodegenerative disease", highlighted recent advancements in neuropharmacology and the therapeutic landscape for neurodegenerative diseases, representing a significant stride forward in our understanding of these complex conditions [...].
摘要
《……》特刊，题为“神经退行性疾病的多靶点药物治疗”，突出了神经药理学的最新进展以及神经退行性疾病的治疗前景，代表了我们对这些复杂病症理解上的重大进步[……]
相似文献
1
Advancing Neuropharmacology and Neurodegenerative Disease Therapy: Bridging Gaps and Paving New Pathways.
Pharmaceuticals (Basel). 2025 Apr 22;18(5):606. doi: 10.3390/ph18050606.
2
Neuropharmacology beyond reductionism - A likely prospect.
Biosystems. 2016 Mar;141:1-9. doi: 10.1016/j.biosystems.2015.11.010. Epub 2015 Dec 23.
3
Neuropharmacology of Organoselenium Compounds in Mental Disorders and Degenerative Diseases.
Curr Med Chem. 2023;30(21):2357-2395. doi: 10.2174/0929867329666220615124412.
4
National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities.
Neuropharmacology. 2023 Jun 1;230:109467. doi: 10.1016/j.neuropharm.2023.109467. Epub 2023 Feb 27.
5
Resting state functional connectivity: its physiological basis and application in neuropharmacology.
Neuropharmacology. 2014 Sep;84:79-89. doi: 10.1016/j.neuropharm.2013.08.023. Epub 2013 Sep 4.
6
Building Bridges In Neuropharmacology: New therapeutic approaches for psychiatric and neurodegenerative disorders.
Br J Pharmacol. 2022 Apr;179(8):1475-1477. doi: 10.1111/bph.15711.
7
Introduction to the College on Problems of Drug Dependence special issue: contemporary advances in opioid neuropharmacology.
Drug Alcohol Depend. 2010 May 1;108(3):153-5. doi: 10.1016/j.drugalcdep.2010.03.001. Epub 2010 Apr 7.
8
The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?
Front Pharmacol. 2014 Jul 10;5:139. doi: 10.3389/fphar.2014.00139. eCollection 2014.
9
Advancing methods in big data capture, integration, classification and liberation.
BMC Res Notes. 2023 Apr 27;16(1):64. doi: 10.1186/s13104-023-06340-z.
10
Drug discovery in neurodegenerative diseases.
Sci Aging Knowledge Environ. 2005 Feb 9;2005(6):pe4. doi: 10.1126/sageke.2005.6.pe4.
本文引用的文献
1
Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer's Disease.
Pharmaceuticals (Basel). 2024 Jun 16;17(6):788. doi: 10.3390/ph17060788.
2
Enzymatic Metabolic Switches of Astrocyte Response to Lipotoxicity as Potential Therapeutic Targets for Nervous System Diseases.
Pharmaceuticals (Basel). 2024 May 16;17(5):648. doi: 10.3390/ph17050648.
3
Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease.
Pharmaceuticals (Basel). 2023 Nov 16;16(11):1620. doi: 10.3390/ph16111620.
4
Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration.
Pharmaceuticals (Basel). 2023 Sep 26;16(10):1359. doi: 10.3390/ph16101359.
5
Multitargeted Virtual Screening and Molecular Simulation of Natural Product-like Compounds against GSK3β, NMDA-Receptor, and BACE-1 for the Management of Alzheimer's Disease.
Pharmaceuticals (Basel). 2023 Apr 20;16(4):622. doi: 10.3390/ph16040622.
Zotero 插件